Canadian Pharma, Biotech and Life Sciences Stocks

Sell Promis Neurosciences, Mackie Research says

An Alzheimer’s drug trial failure has caused Mackie Research analyst André Uddin to downgrade his rating for Promis Neurosciences (Promis Neurosciences Stock Quote, Chart TSX:PMN) from “Speculative Buy” to “Sell” in a client update on Thursday. A Phase III trial conducted by American bio ...

Cipher Pharma has a huge upside, says Echelon Wealth

Look for Cipher Pharmaceuticals (Cipher Pharmaceuticals Stock Quote, Chart TSX:CPH) to break out of its slump in 2019, says Doug Loe of Echelon Wealth Partners. Loe gives a 12-month return of 257 per cent for the stock, saying the specialty pharma company’s pipeline prospects are encouraging. Cip ...

Aurinia Pharma has a 56 per cent upside, Mackie Research says

Mackie Research analyst André Uddin is bullish on Canadian drug development company Aurinia Pharmaceuticals (Aurinia Pharmaceuticals Stock Quote, Chart NASDAQ:AUPH), whose calcineurin inhibitor drug voclosporin could reach global sales of more than $770 million in ten years time. BC-based Aurinia ...

Cipher Pharmaceuticals has a 155 per cent upside, Mackie Research says

Expect top line growth to reaccelerate for Cipher Pharmaceuticals (Cipher Pharmaceuticals Stock Quote, Chart TSX:CPH), says Mackie Research analyst André Uddin, who calls CPH a cheap pickup for investors. Canadian specialty pharma company Cipher released its fourth quarter and full year 2018 finan ...

Canadian Market Review 2019-03-15

The $TSX continues to inch higher week after week, suggesting that my caution in February was unwarranted. However, this week marks options expiration, as I mentioned early in the month. While the US market seems to find these dates important, the Canadian market finds them definitely importan ...

Profound Medical is an undervalued life sciences stock for 2019, Echelon says

2018 didn’t shape up exactly the way he had imagined, but Echelon Wealth Partners analyst Doug Loe thinks 2019 could be Profound Medical’s (Profound Medical Stock Quote, Chart TSX:PRN) year. On March 7, Profound reported its Q4 and fiscal 2018 results. In the fourth quarter, the company lost $4 ...

Mackie Research maintains “Hold” rating on Theratechnologies

Positive new data for Theratechnologies’ (Theratechnologies Stock Quote, Chart TSX:TH) HIV treatment Trogarzo isn’t moving the needle for Mackie Research Capital analyst André Uddin. On Friday, Theratech announced that new data presented at the 26th annual Conference on Retroviruses and Opport ...

Canopy Growth Corp needs five or six good years to justify current valuation, this investor says

All eyes will be on Canopy Growth Corp (Canopy Growth Corp Stock Quote, Chart TSX:WEED) next week as the cannabis kingpin releases its quarterly financials, the first since the start of legal adult-use pot in Canada. Those quarterly numbers are the dose of reality that discerning investors are look ...

Canopy Growth could become bigger than Constellation Brands, Bruce Linton says

At this year’s Cantech Investment Conference, Canopy Growth CEO and co-founder Bruce Linton sat down with Globe and Mail reporter Jameson Berkow and held forth on all things cannabis. There were multiple highlights from the affable and effusive Linton. On the October 17 rollout of recreational ma ...

Could Roche’s Alzheimer’s drug failure be Promis Neurosciences gain?

News that Swiss multinational Roche Holding AG is shutting down two late-stage studies of its Alzheimer drug has been greeted as the latest in a series of disappointments concerning the search for an effective treatment for the devastating disease, but Elliot Goldstein CEO of Promis Neurosciences s ...